Delving into the Latest Updates on Probiotic(Mendes) with Synapse

Overview

Basic Info

Drug Type

Probiotics

Synonyms

Vivomixx

Target-

Action

modulators

Mechanism

Bacteria replacements, Microbiome modulators

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Mendes

Active Organization

Mendes

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Autism, a disorder influenced by both genetic and environmental factors, presents significant challenges for prevention and treatment. While maternal-infant gut microbiota has been a focus in autism research, preventive strategies targeting maternal gut microbiota remain underexplored. This study demonstrates that prenatal probiotic intake can effectively prevent maternal separation-induced autistic-like behaviors in offspring without altering the embryonic neurodevelopment in mice. Using specific PCR primers and cross-fostering experiments, we traced the vertical transmission of probiotics, primarily via fecal/vaginal contamination. Early probiotic colonization conferred resilience against stress-induced gut pathogenic microbes and Th17-mediated peripheral inflammation while significantly inhibiting hypermyelination and neuroinflammation linked to systemic inflammation. Microbial metabolites like tyrosol and xanthurenic acid alleviated neuroinflammation and hypermyelination in vitro, though the causal relationship among neuroinflammation, hypermyelination, and autism in vivo requires further validation. These findings underscore the importance of the maternal-infant microbiota transmission window in autism prevention and highlight the clinical potential of prenatal probiotic interventions.

31 Dec 2025·Gut Microbes

Gut dysbiosis-induced vitamin B6 metabolic disorder contributes to chronic stress-related abnormal behaviors in a cortisol-independent manner

Article

Author: Qing, Wenxiang ; Tong, Jianhua ; Ma, Xin ; Chen, Jie ; Le, Yuan ; Ma, Daqing ; Chen, Huimin ; Ouyang, Wen ; Tong, Jianbin ; Duan, Kaiming ; Chen, Hui

Chronic stress can result in various conditions, including psychological disorders, neurodegenerative diseases, and accelerated brain aging. Gut dysbiosis potentially contributes to stress-related brain disorders in individuals with chronic stress. However, the causal relationship and key factors between gut dysbiosis and brain disorders in chronic stress remain elusive, particularly under non-sterile conditions. Here, using a repeated restraint stress (RRS) rat model, we show that sequential transplantation of the cecal contents of different RRS stages to normal rats reproduced RRS-induced core phenotypes, including abnormal behaviors, increased peripheral blood corticosterone and inflammatory cytokines, and a unique gut microbial phenotype. This core phenotypic development was effectively inhibited with probiotic supplement. The RRS-induced unique gut microbial phenotypes at the genus level were positively or negatively associated with the levels of 20 plasma metabolites, including vitamin B6 metabolites 4-pyridoxic acid and 4-pyridoxate. Vitamin B6 supplement during RRS alleviated weight loss, abnormal behaviors, peripheral inflammation, and neuroinflammation, but did not affect the peripheral corticosterone levels in chronic stressed rats. Dampening inflammatory signaling via knocking out caspase 11 or caspase 1 inhibitor abolished RRS-induced abnormal behaviors and peripheral and neuroinflammation but did not decrease peripheral corticosterone in mice. These findings show that gut dysbiosis-induced vitamin B6 metabolism disorder is a new non-hypothalamic-pituitary-adrenal axis mechanism of chronic stress-related brain disorders. Both probiotics and vitamin B6 supplement have potential to be developed as therapeutic strategies for preventing and/or treating chronic stress-related illness.

31 Dec 2025·Gut Microbes

Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure

Article

Author: Tao, Junyi ; Gomez, Daniel ; Antoine, Danielle ; Singh, Salma ; Abu, Yaa ; Truitt, Bridget ; Roy, Sabita

The gut microbiome has emerged as a promising target for modulating adverse effects of opioid exposure due to its significant role in health and disease. Opioid use disorder (OUD) has become increasingly prevalent, specifically in women of reproductive age, contributing to an increased incidence of offspring exposed to opioids in utero. Recent studies have shown that prenatal opioid exposure (POE) is associated with notable changes to the maternal gut microbiome, with subsequent implications for the offspring's microbiome and other adverse outcomes. However, the role of the gut microbiome in mediating sex-based differences in pain sensitivity has not yet been investigated. In this study, both male and female C57BL/6 offspring were used to determine sex-based differences in nociception and gut microbial composition as a result of POE. Our data reveals significant sex-based differences in offspring prenatally exposed to opioids. The gut microbiome of opioid-exposed females showed an enrichment of commensal bacteria including Lactobacillus compared to opioid-exposed males. Additionally, POE females demonstrated decreased nociceptive sensitivity, while males demonstrated increased nociceptive sensitivity. RNA sequencing of the prefrontal cortex showed sex-based differences in several canonical pathways, including an increase in the opioid signaling pathway of opioid-exposed females, which was not observed in males. Microbiome modification via maternal probiotic supplementation attenuated sex-based differences throughout the early stages of life. Together, our study provides further insight on sex-based differences arising from POE and highlights the pivotal role of the gut microbiome as a modifiable target for mitigating its negative effects.

100 Deals associated with Probiotic(Mendes)

Login to view more data

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESPE2023	Not Applicable	Diabetes Mellitus, Type 1	-	probiotic	(fsivshtrtt) = aibemkhmnx ammxokgkms (gbwdfjhwpb ) View more	Positive	21 Sep 2023
IRCT201706075623N119 (Pubmed \| Clin Nutr)	Phase 3	Diabetes, Gestational	87	Vitamin D + Probiotic	(zomapjqssj) = xtsmucfclw orqnbylqlv (zryuylzawo ) View more	-	01 Oct 2019
IRCT2017072333551N2 (Pubmed \| BMC Psychiatry)	Phase 2	Schizophrenia	60	Vitamin D3 + Probiotic	wsgstgfpzh(ixhcszakgm) = jdapimpntl obqdwrcosj (umtyjsrubq ) View more	-	21 Feb 2019
				Placebo	(zskrgcqmar) = hnamrscxhq vrksdipetz (wreniusfif ) View more
IRCT2017073033941N4 (Pubmed \| Prog Neuropsychopharmacol Biol Psychiatry)	Phase 3	Diabetes Mellitus, Type 2 \| Coronary Disease	60	Vitamin D + Probiotic	jnjxyahayc(ejwczjdoxi) = etocwpjndv tphhkzdlnj (nydqiddaux ) View more	-	08 Jun 2018
				vitamin D (Placebo)	jnjxyahayc(ejwczjdoxi) = ojebptafak tphhkzdlnj (nydqiddaux ) View more
NHANES (ASN2015)	Not Applicable	Albuminuria	6,853	Probiotic (Frequent consumers of yogurt)	(rgtatawxvd) = awfawhpgov pstgltfelw (ilrlaielrm ) View more	Positive	03 Nov 2015
				Probiotic (Non-consumers of yogurt)	-
ERS2015	Not Applicable	-	185	Lactobacillus GG (LGG) supplementation	(czgsdmnqti) = gghusyvfrn bdkdsmjvtx (dfevztpvvs ) View more	Negative	01 Sep 2015
				probiotic	(czgsdmnqti) = lsmbdxexlq bdkdsmjvtx (dfevztpvvs ) View more